PIK3CA and breast carcinoma: Despite the high incidence of PIK3CA mutations in breast carcinoma and their putative prognostic role, the therapeutic targeting of the PIK3CA gene has fallen short of expectations, with results from clinical trials with pan-PI3K inhibitors in solid tumors largely disappointing, namely due to unfavorable toxicity versus clinical benefit ratio (Hanker et al., 2019).